Sector News

Warren Wang named SVP and President of Asia Pacific of Boston Scientific

October 13, 2017
Life sciences

Boston Scientific Corporation announces the appointment of Warren Wang as senior vice president and president, Asia Pacific, effective January 1, 2018. He will serve as a member of the Boston Scientific executive committee and have responsibility for overseeing the company’s continued growth in the Asia Pacific region.

With extensive experience in the medical technology industry, Warren currently serves as president and managing director, North Asia, Boston Scientific, and leads the company’s business in China, Hong Kong, Taiwan and South Korea. Wang joined Boston Scientific in 2012 as vice president and managing director for China.

“The opportunities and complexities of the Asia Pacific healthcare market offer new inroads and alternatives in the advancement of market appropriate medical technology and access to high quality care,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “Warren’s experience and keen sense for developing new business collaborations have had a strong influence on our growth in North Asia. We look forward to Warren’s continued leadership in his new role as we pursue our mission of transforming the lives of patients through our innovative medical solutions.”

Warren will succeed Supratim Bose, who will retire as executive vice president and president, Asia Pacific, Middle East and Africa (AMEA), at the end of 2017.

“I thank Supratim for his many contributions during his distinguished career at Boston Scientific,” said Mahoney. “The AMEA region has grown significantly over the last five years. Supratim’s leadership and commitment to our customers and patients will have lasting impact on Boston Scientific and the medical device industry.”

Prior to joining Boston Scientific, Warren held roles of increasing responsibility with the medical device businesses of Johnson & Johnson, including general manager of the Orthopedics group in China, and leadership positions for the company’s surgical and orthopedics franchises.

Source: Boston Scientific

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).